ea0090p366 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023
Haddad Aiman
, Sharma Angelica
, Lee Tse Tsz
, Taufik Bara
, Seetho Ian
Introduction: Sodium Glucose Co-transporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering therapies that have demonstrated prognostic benefit in the management diabetes, heart failure and renal impairment. National Institute for Health and Clinical Excellence (NICE) guidance recommends offering SGLT2i, in addition to metformin, first-line in individuals with type 2 diabetes (T2D) and chronic heart failure/ established atherosclerotic cardiovascular disease. Howev...